Bacteriophage Therapy Market Size, Share, Growth, And Industry Analysis, By Type (Oral, Topical, Parenteral), By Application (Organ Transplantation, Bacterial Infections, Alcoholic Hepatitis, Other), Regional Insights, and Forecast To 2033

• 

   Request a Free Sample To Get More Information on this Market

BACTERIOPHAGE THERAPY MARKET REPORT OVERVIEW

The global bacteriophage therapy market size was anticipated to be worth USD 0.04 billion in 2024 and is expected to reach USD 0.09 billion by 2033 at a CAGR of 9.6% during the forecast period.

Bacteriophages are viruses that only kill and target bacteria. They are among the most common biological entities capable of combating and eliminating multidrug-resistant bacteria. When all other antibiotics fail to treat an infection, phages can eradicate the bacteria that is causing the infection, allowing medical professionals to preserve a life. Bacteriophages are being studied as an antibiotic substitute. In this therapy, viruses are used to inject their genetic material into bacteria and proliferate using their host machinery. This phage therapy is used in patients' bodies to cure or prevent bacterial disorders. Bacteriophage therapy is also crucial in molecular biology and technical research. These features increase the likelihood of pharmaceutical development. Phages are another name for Bacteriophages.

Antimicrobial-resistant illnesses are caused by bacteria such as salmonella typhi, pseudomonas aeruginosa, and mycobacterium tuberculosis. These infections are causing an increase in treatment costs. This factor will almost certainly drive the bacteriophage industry in the near future.

COVID-19 IMPACT

"COVID-19 pandemic hampered clinical trials hence impeded market growth"

The COVID-19 pandemic has been unprecedented and staggering, with the bacteriophage therapy market experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden rise in CAGR is attributable to the market’s growth and demand returning to pre-pandemic levels.

Since the COVID-19 viral outbreak in December 2019, the disease has spread to over 100 countries, causing the World Health Organisation to declare it a public health emergency. Furthermore, the COVID-19 pandemic created substantial difficulties on numerous fronts to players in the global bacteriophage therapy market. Because of transportation facility inconsistencies, obtaining raw materials for the production of medicine formulations was a major challenge. Furthermore, due to an increasing patient population with COVID-19 and other life-threatening illnesses, goods distributors were experiencing unpredictable demand from retailers. The COVID-19 pandemic hampered clinical trials in the United States, hurting key companies throughout the industry. Furloughs, social-distancing protocols, financial losses, and patient safety concerns all had an impact on investigative site capabilities. Sponsors, CROs, and other drug development support companies have relocated to remote work settings. As a result of the COVID-19 pandemic, an estimated 80% of non-COVID-19 trials were halted or interrupted.

LATEST TRENDS

"Increase in the number of R & D activities leading market expansion"

Furthermore, the market's expansion is being propelled by an increase in the number of R&D activities. This will give advantageous chances for the expansion of the bacteriophage therapy industry. For example, the US Food and Drug Administration authorised a proposal from physician-scientists at the University of California San Diego School of Medicine in January 2019 to conduct the first U.S. clinical trial of a bacteriophage-based intravenous therapy. The intended experiment will be carried out in collaboration with AmpliPhi Biosciences Corporation, a San Diego-based biotechnology corporation.

BACTERIOPHAGE THERAPY MARKET SEGMENTATION

By Type

According to type, the market can be segmented into Oral, Topical, Parenteral. Oral is anticipated to be the leading segment.

By Application

Based on application, the market can be divided into Organ Transplantation, Bacterial Infections, Alcoholic Hepatitis, Other. Organ Transplantation will be dominating segment.

DRIVING FACTORS

"high prevalence of Foodborne disease and Increasing healthcare infrastructure investment which aids market expansion"

The global increase in the prevalence of foodborne infections will be a main driver of the market's growth rate. Foodborne diseases caused by rotten food are on the rise. In rotting food, pathogenic bacteria and viruses can be found. According to the World Health Organisation, over 600 million people (almost one out of every ten people on the earth) will become ill and 420,000 will die as a result of contaminated food in 2019, resulting in a loss of 33 million healthy life years (DALYs). Furthermore, with 125,000 deaths per year, children under the age of five face 40% of the burden of foodborne disease. This factor is moving the market for bacteriophages therapy ahead. Another key element affecting the growth rate of the bacteriophages therapy market is rising healthcare expenditure, which aids in infrastructure improvement. Furthermore, several government organisations intend to improve healthcare infrastructure by boosting financing, which would have an impact on market dynamics.

"Rising occurrence of antibiotic-resistant illnesses drives market expansion"

The rising prevalence of antibiotic-resistant infections is expected to drive market expansion. Antimicrobial-resistant infections are becoming more common, resulting in greater healthcare spending and an increase in the number of deaths. According to the Centres for Disease Control and Prevention (CDC), roughly 2 million Americans will get an antibiotic-resistant infection in 2019, with at least 23,000 dying each year. In 2016, over 490,000 people worldwide were infected with multidrug-resistant tuberculosis, according to the World Health Organisation. Drug resistance complicates the treatment of patients suffering from various diseases such as malaria and HIV.

RESTRAINING FACTORS

"high cost of bacteriophages therapy would impede the market growth "

The high cost of bacteriophages therapy would impede the growth rate of the bacteriophages therapy market during the forecast period of 2025-2033. The bacteriophage therapy market will face challenges due to a lack of healthcare infrastructure in developing economies and a stringent regulatory environment. Furthermore, a lack of awareness among people and the availability of alternatives may hinder and impede the market's growth rate during the projection period of 2025-2033.

• 

   Request a Free Sample To Get Analysis on Major Geographic Market

BACTERIOPHAGE THERAPY MARKET REGIONAL INSIGHTS

"North America dominates the market throughout the projection period"

North America dominates the bacteriophages therapy market in terms of market share and revenue and will continue to do so during the forecast period. This is because lytic bacteriophage provides quick recovery and therapeutic impact, and rising healthcare expenditure would further boost the market's development rate in this region. Furthermore, the presence of major key players and greater acceptance of innovative technologies will drive this market's growth pace.

KEY INDUSTRY PLAYERS

"Key Players Focus on Partnerships to Gain a Competitive Advantage "

Prominent market players are making collaborative efforts by partnering with other companies to stay ahead of the competition. Many companies are also investing in new product launches to expand their product portfolio. Mergers and acquisitions are also among the key strategies used by players to expand their product portfolios.

List of Top Bacteriophage Therapy Companies

• Armata Pharmaceuticals, Inc. (U.S.)
• Eliava Biopreparations Ltd. (Georgia)
• Pherecydes Pharma (France)
• Intralytix, Inc. (U.S.)
• Phagelux Inc. (China)
• Nextbiotics (U.S.)
• InnoPhage, Ltd (Hong Kong)
• Locus Biosciences, Inc. (U.S.)
• TechnoPhage (Portugal)
• Eligo Bioscience SA (France)
• Phagomed Biopharma GmbH.
• PhagePro, Inc.
• Adaptive Phage Therapeutics, Inc. (U.S.)
• EnBiotix, Inc. (U.S.)
• BiomX Ltd. (Israel)
• NtODEWORLD. Inc. (U.S.)
• Fixed-phage Ltd. (U.K.)
• Micreos BV (Netherlands)
• ContraFect Corporation

REPORT COVERAGE

This research profiles a report with extensive studies that take into description the firms that exist in the market affecting the forecasting period. With detailed studies done, it also offers a comprehensive analysis by inspecting the factors like segmentation, opportunities, industrial developments, trends, growth, size, share, and restraints. This analysis is subject to alteration if the key players and probable analysis of market dynamics change.